What are low-molecular-weight heparins (LMWHs)?

LMWHs are a group of drugs that are used to prevent and treat blood clots (thrombosis). They are blood thinners, also known as anticoagulants, used for the prevention and treatment of blood clots which can be life-threatening. They are blood thinners, also known as anticoagulants, used for the prevention and treatment of blood clots which can be life-threatening.

**Why did we do this review?**

In 2014, the Ministry of Health and Long-Term Care initiated an initiative to modernize the public drug formulary in Ontario. The Ontario Drug Policy Research Network (ODPRN) conducted multiple studies on the recommended use and accessibility of low-molecular-weight heparins (LMWHs) using various research methods as part of this initiative.

**Current listing**

In Canada, there are four LMWHs commercially available: enoxaparin, dalteparin, nadroparin, and tinzaparin.

**Availability**

In Canada, there are four LMWHs commercially available: enoxaparin, dalteparin, nadroparin, and tinzaparin.

**Other considerations**

- **Dosing and monitoring:**
  - Enoxaparin is available in a range of dosages for children and adults.
  - Dalteparin is available in a range of dosages for adults and children.
  - Nadroparin is available in a range of dosages for adults and children.
  - Tinzaparin is available in a range of dosages for adults and children.

- **Contraindications:**
  - LMWHs are generally contraindicated in patients with active bleeding.
  - LMWHs are usually contraindicated in patients with recent bleeding.
  - LMWHs are generally contraindicated in patients with a history of heparin-induced thrombocytopenia (HIT).
  - LMWHs are usually contraindicated in patients with a history of HIT.

- **Adverse effects:**
  - LMWHs may cause minor bleeding, which is often not serious.
  - LMWHs may cause minor bleeding, which is often not serious.
  - LMWHs may cause minor bleeding, which is often not serious.
  - LMWHs may cause minor bleeding, which is often not serious.

- **Drug interactions:**
  - LMWHs may interact with a number of other medications.
  - LMWHs may interact with a number of other medications.
  - LMWHs may interact with a number of other medications.
  - LMWHs may interact with a number of other medications.

- **Monitoring:**
  - LMWHs are usually monitored by measuring the international normalized ratio (INR) or partial thromboplastin time (PTT).
  - LMWHs are usually monitored by measuring the international normalized ratio (INR) or partial thromboplastin time (PTT).
  - LMWHs are usually monitored by measuring the international normalized ratio (INR) or partial thromboplastin time (PTT).
  - LMWHs are usually monitored by measuring the international normalized ratio (INR) or partial thromboplastin time (PTT).

- **Special considerations:**
  - LMWHs are generally not recommended for use in patients with severe renal impairment.
  - LMWHs are generally not recommended for use in patients with severe renal impairment.
  - LMWHs are generally not recommended for use in patients with severe renal impairment.
  - LMWHs are generally not recommended for use in patients with severe renal impairment.

- **Additional resources:**
  - ODPRN website: www.odprn.ca
  - Twitter: @ODPRN

**Price negotiations:**

- The Ontario Drug Policy Research Network (ODPRN) has conducted multiple studies on the recommended use and accessibility of low-molecular-weight heparins (LMWHs) using various research methods as part of an initiative to modernize the public drug formulary in Ontario.

**Visit the ODPRN website:**

www.odprn.ca

For more information about the work we do.

**Reasons to participate:**

- To be part of a network that is working to improve the health and safety of patients in Ontario.
- To be part of a network that is working to improve the health and safety of patients in Ontario.
- To be part of a network that is working to improve the health and safety of patients in Ontario.
- To be part of a network that is working to improve the health and safety of patients in Ontario.

**For more information:**

Visit the ODPRN website: www.odprn.ca

**Twitter:**

@ODPRN

www.odprn.ca

For more information about the work we do.

**Reasons to participate:**

- To be part of a network that is working to improve the health and safety of patients in Ontario.
- To be part of a network that is working to improve the health and safety of patients in Ontario.
- To be part of a network that is working to improve the health and safety of patients in Ontario.
- To be part of a network that is working to improve the health and safety of patients in Ontario.

**For more information:**

Visit the ODPRN website: www.odprn.ca

**Twitter:**

@ODPRN

www.odprn.ca

For more information about the work we do.

**Reasons to participate:**

- To be part of a network that is working to improve the health and safety of patients in Ontario.
- To be part of a network that is working to improve the health and safety of patients in Ontario.
- To be part of a network that is working to improve the health and safety of patients in Ontario.
- To be part of a network that is working to improve the health and safety of patients in Ontario.

**For more information:**

Visit the ODPRN website: www.odprn.ca

**Twitter:**

@ODPRN

www.odprn.ca

For more information about the work we do.